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Abstract
The role of genetic variability in dementia with Lewy bodies (DLB) is now indisputable, however data
regarding copy number variation (CNV) in this disease has been lacking. Here, we used whole-
genome genotyping of 1,454 DLB cases and 1,525 controls to assess copy number variability. We
used two algorithms to confidently detect CNVs, performed a case-control association analysis,
screened for candidate CNVs previously associated with DLB-related diseases, and performed a
candidate gene approach to fully explore the data. We identified five CNV regions with a significant
genome-wide association to DLB, two of these were only present in cases and absent from publicly
available databases: one of the regions overlapped LAPTM4B, a known lysosomal protein; whilst the
other overlapped the NME1 locus and SPAG9. We also identified DLB cases presenting CNVs in
genes previously associated with DLB or related neurodegenerative diseases, namely SNCA and
MAPT. To our knowledge, this is the first study reporting genome-wide CNVs in a large DLB cohort.
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1. Introduction
Dementia with Lewy bodies (DLB) is a common and complex form of dementia and its diagnosis
can often be complicated by phenotypic similarities with Alzheimer's disease (AD), Parkinson’s
disease (PD) or even Frontotemporal dementia (FTD) (Claassen et al., 2008; Heidebrink, 2002). A
more accurate DLB diagnosis is usually obtained by integrating clinical and pathological data from
brain autopsy (McKeith et al., 2017).
Genetic studies in DLB have been limited, certainly in comparison with studies on AD or PD, for a
number of reasons, most notably because DLB has not been historically considered a genetic
disease, given the lack of multiplex kindreds where the disease segregates. Additionally, large
cohorts of patients are difficult to collect given the frequency of the disease and the rate of
misdiagnosis. Despite this, recent studies have conclusively shown that there is a role for genetics
in the etiology of DLB (Bras et al., 2014; Guerreiro et al., 2018, 2016; Nalls et al., 2013). Exome
sequencing studies have been performed in small cohorts; as have case studies and Sanger
sequencing of specific target genes (Clark et al., 2009; Keogh et al., 2016; Koide et al., 2002;
Ohtake et al., 2004). Copy number variants (CNVs) have not been assessed thus far in DLB,
particularly in an unbiased manner and at a genome-wide level.
CNVs have been widely studied in a number of neurological conditions, particularly in
developmental phenotypes such as schizophrenia (SCZ) and autism (Glessner et al., 2009;
Marshall et al., 2017; McCarthy et al., 2009) where several microdeletions and microduplications
have been found to be associated with both diseases (Bassett et al., 2017; Cook et al., 1997;
McCarthy et al., 2009; Stefansson et al., 2008; Weiss et al., 2008). In these phenotypes CNVs play
a prominent role in the disease genetic architecture.
Several studies have analyzed CNVs in AD, where APP duplications have been unequivocally
shown to cause disease (Delabar et al., 1987; Ghani et al., 2012; Swaminathan et al., 2012, 2011;
Zheng et al., 2015, 2014). In PD, pathogenic CNVs are also known to occur in SNCA and PARK2
(Chartier-Harlin et al., 2004; Ibáñez et al., 2004; Lesage et al., 2008; Waters and Miller, 1994).
Together, these data show that CNVs are an important mutational event in neurological conditions.
Here, we report the first genome-wide analysis of CNVs in DLB in a large cohort of patients, many
of which with neuropathology diagnoses of DLB. We performed a case-control association study
that was complemented by discovery stage analyses guided by candidate genes and CNVs
previously reported as being associated with DLB-related neurodegenerative diseases.
2. Materials and Methods
2.1. Sample selection
A total of 1,454 patients diagnosed with DLB and of European ancestry were selected for this study.
Diagnosis of DLB was made according to clinical or pathological criteria (McKeith et al., 2005).
Briefly, these included 298 clinically diagnosed and 1,156 neuropathologically diagnosed cases.
Detailed sample and processing information has been described previously (Guerreiro et al., 2018).
Data from 1,525 control samples was obtained from The Genetic Architecture of Smoking and
Smoking Cessation study (phs000404.v1.p1) publicly available at the database of Genotypes and
Phenotypes (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/study.cgi?study_id=phs000404.v1.p1.) Supplementary Figure 1 shows an overview of the
study design, different QC steps and analyses performed.
2.2. Genotyping, quality control and CNV calling
Seven hundred and fifty four DLB samples were genotyped on HumanOmni2.5Exome-8 v1.0.B
Illumina arrays, and 700 DLB samples were genotyped using Infinium OmniExpress-24 v1.2.A1
Illumina arrays (Illumina, Inc., CA, USA). Control samples were genotyped on HumanOmni2.5-4
v1.D arrays (Illumina, Inc., CA, USA). Intensity files were analysed using GenomeStudio v2011.1
software (Illumina, Inc., CA, USA) along with the respective manufacturer’s cluster files. Quality
control (QC) procedures were performed in GenomeStudio (GS) prior to CNV analysis as described
by Jarick and colleagues (Jarick et al., 2014). In short, samples with call rates lower than 0.97 were
filtered out. SNP statistics were re-calculated following visual inspection of B allele frequency (BAF)
and Log R ratio (LRR) plots. SNPs with GenTrain Scores below 0.7 were excluded. Lastly, samples
with substantial cryptic relatedness scores (PI_HAT >0.1) were removed, as previously described
(Guerreiro et al., 2018).
CNV calls were generated using two different algorithms: cnvPartition v2.3.0 (Illumina, Inc). and
PennCNV v1.0.4 (Wang et al., 2007). CNV calling based on cnvPartition was performed by GS with
default parameters. For PennCNV, probe positions, LRR and BAF values for samples that passed
QC procedures were exported from GS. Population frequency of the B allele (PFB) files were
calculated for each array separately. All Smoking Cessation samples were used to generate CNVs
in cnvPartition and PennCNV, but only a subset of the best performing 700 samples was used for
the compilation of the PFB file in PennCNV to match the number of samples used for cases.
PennCNV GC-model files were then created based on these PFBs. Lastly, CNVs were inferred by
PennCNV using the hidden Markov model (HMM) and the GC-model for wave adjustment. Calls for
the X chromosome were generated separately. Chromosomes Y, MT and XY were not analyzed.
2.3. CNV quality control and analysis
To improve the quality of CNVs, only calls generated by both algorithms were kept, while calls made
by a single algorithm or calls of opposing type (for example, assigned as a deletion by one algorithm
and as duplication by the other) were discarded. Adjacent CNVs were merged if the length of the
sequence between them was smaller than 50% of the length of the larger CNV. CNVs were
excluded if they were overlapping telomeres, centromeres, known segmental duplications, the
immunoglobulin or the T cell receptor loci. Samples having LRR SD > 0.28, BAF drift > 0.002,
Waviness Factor (WF) > 0.04, or having more CNV calls than 3*SD + median were excluded
(Marshall et al., 2017; Need et al., 2009).
To identify potentially pathogenic CNVs, we analyzed CNVs spanning known genes. We used the
Database of Genomic Variants (DGV) (http://dgv.tcag.ca/dgv/app/home, accessed November 2017)
to determine the population frequency of CNVs (MacDonald et al., 2014). This information was
complemented with the frequency from clinical samples available in DECIPHER v9.18
(https://decipher.sanger.ac.uk/, accessed November 2017).
2.4 Case-control association analysis
Case-control association analysis was implemented using ParseCNV (Glessner et al., 2013).
Standard ParseCNV quality metrics were used to filter out low quality results. CNVs that were
genome-wide significant (p-value < 5x10-4 as suggested by (Glessner et al., 2013)), had a minimum
length of 50 kb, and passed visual inspection in GS were selected for further analyses.
2.5. Candidate CNVs approach
CNVs previously described in AD (Ghani et al., 2012; Heinzen et al., 2010; Swaminathan et al.,
2012, 2011; Zheng et al., 2015, 2014), PD (Bademci et al., 2010; Liu et al., 2013; Mok et al., 2016;
Pankratz et al., 2011) and FTD (Gijselinck et al., 2008) were specifically investigated in these data
(Supplementary Table 1). This analysis was performed in the complete set of CNV results after
QC, disregarding the filters used for the case-control association analysis performed by ParseCNV.
2.6. Candidate genes approach
CNVs located in known AD, PD, FTD and DLB genes were also assessed (Brás et al., 2015;
Guerreiro et al., 2018, 2015, 2013; Jansen et al., 2015; Keogh et al., 2016; Koide et al., 2002;
Ohtake et al., 2004; Saitoh et al., 1995). Supplementary Table 2 lists all genes studied using this
approach.
3. Results
3.1. CNV calling and QC steps
After QC steps at the GS level, a total of 2,819 samples (1,294 cases and 1,525 controls) remained
for further analyses. From the 754 DLB samples genotyped with HumanOmni2.5 arrays, 616
(81.7%) samples were kept and from the 2,567,845 probes in this array, 2,496,600 (97.2%) passed
quality control. Six hundred and seventy-eight (96.9%) samples of the 700 samples genotyped with
OmniExpress arrays passed quality control and from the 713,599 probes available in this chip,
698,680 (97.9%) probes remained. All controls from the Smoking Cessation database had good
quality genotypes (call rate > 0.97) and, consequently, no samples were excluded, and 2,390,384
(97.8%) of the 2,443,177 probes were kept.
After combining the results obtained by the two CNV calling algorithms (cnvPartition and PennCNV),
excluding samples due to their relatedness and performing the PennCNV QC steps on the LRR and
BAF values and number of calls, a final number of 2,615 individuals (1,187 DLB cases and 1,428
control samples) and 80,416 CNVs were analysed.
3.2. Case-control association analysis
Of the 494 CNV regions (CNVR) resulting from the ParseCNV analysis, only 5 passed QC checks
and were statistically significant (Table 1). Of these, two of the regions were not present in our
control population or in public databases: a deletion overlapping LAPTM4B (p=6.29x10-7) and a
CNVR overlapping SPAG9-NME1-NME2 (p=2.72x10-4) (Figure 1).
3.3. Candidate CNVs approach
Five CNVs previously associated with DLB-related neurodegenerative diseases were found in DLB
patients (Table 1). Two of these were present in the control group with a higher frequency than in
the patients’ group, and the remaining three are described in public databases and are detailed
next. The duplication identified on chromosome 12 overlapping DDX11 and OVOS2 has a
frequency tenfold higher in DGV than in the DLB cohort. The 16p11.2 microduplication found in one
DLB patient, has a frequency of 1.69x10-4 in the DECIPHER database but does not occur in any
control samples or in the DGV database. One of the CNVs that was previously significantly
associated with AD locates at chr8:2792874-4852328 and overlaps CSMD1 (Swaminathan et al.,
2011). At this locus, we identified over 100 CNVs in cases and controls. Therefore, in Table 1, we
only report the shorter interval that showed suggestive significance in the case-control association
analysis.
3.4. Candidate genes approach
We investigated CNVs in genes known to be associated with diseases that are related to DLB
(Supplementary Table 2) and identified a total of 8 CNVs (Table 1). These included one
duplication in APP occurring in a clinically diagnosed case. This large duplication is not present in
the databases or in the control cohort. Two samples were found to carry duplications spanning
MAPT, and one neuropathologically diagnosed patient was found to carry a SNCA duplication
(Figure 2). PARK2 was found to have many copy number losses and gains in controls (n=28) and
cases (n=13) but none as homozygous. A duplication including CHCHD10 was also identified in a
neuropathologically diagnosed DLB patient.
4. Discussion
We performed a systematic analysis of CNVs in a large cohort of DLB patients using three main
approaches. The first of these approaches was a case-control association analysis which resulted in
five significant CNVRs that have not been previously described as associated with the disease. The
most significant result from this analysis was a deletion spanning a lysosome-associated
transmembrane protein, LAPTM4B. Intraneuronal alpha-synuclein clearance likely occurs through a
variety of mechanisms in order to maintain protein homeostasis. However, recent data has
highlighted the importance of lysosomal pathways for degradation of this protein (Webb et al.,
2003). While we cannot directly link this CNV to the development of DLB in these cases, it is
interesting that a lysosomal enzyme is the top hit in our association analysis, given the prominent
role of the lysosome in Lewy body diseases. Interestingly, a member of the same protein family,
LAPTM5, was one of the top hits for incidental DLB in a recent network analysis study (Santpere et
al., 2017).
Also associated with DLB and absent from publicly available databases was a deletion overlapping
the NME1 locus. NME1 is involved in purine metabolism, which has been reported to be disrupted
in AD, PD and Creutzfeldt–Jakob disease. NME1 mRNA was also found to be reduced in these
diseases (Ansoleaga et al., 2016, 2015; Garcia-Esparcia et al., 2015). Here, we identified a deletion
at the 3’-end NME1 which could be consistent with a reduced expression of the gene in DLB,
although this was not tested in the present study.
Using a candidate gene approach where we analyzed genes known to have a role in DLB and DLB-
related diseases we identified several CNVRs of interest. The hallmark of DLB at autopsy is the
accumulation of alpha-synuclein protein within neurons and their processes, termed Lewy bodies
and Lewy neurites (Spillantini et al., 1997). Variants in the SNCA gene, which encodes alpha-
synuclein, have been previously associated with the risk of developing DLB (Bras et al., 2014;
Guerreiro et al., 2018). In addition to point mutations, CNVs including SNCA are known to cause
PD, and over the past years evidence suggested that this gene may also be duplicated in DLB.
Nishioka and colleagues identified a PD family with a duplication spanning all of SNCA and MMRN1
where the proband was later neuropathologically diagnosed as DLB (Nishioka et al., 2006b; Obi et
al., 2008). Four neuropathologically diagnosed DLB cases presented a large duplication from DSPP
to PDLIM5 including SNCA, three of these were heterozygous and one was homozygous (Ikeuchi et
al., 2008). A duplication in SNCA was also described in a probable DLB patient in a study with 99
cases (Meeus et al., 2012). Here, we add to this body of evidence, by identifying another patient
neuropathologically diagnosed with DLB carrying a SNCA duplication. In our DLB cohort this
duplication shows a similar frequency to that provided by DGV. This frequency in DGV results from
two entries in the database. When looking in more detail at these entries, they are associated with
the same Human Genome Diversity Project (HGDP) sample from Cambodia (HGDP00721). Given
that information for each HGDP samples is limited to sex of the individual, population and
geographic origin, it is possible this sample originated from a PD or DLB patient; or from an
asymptomatic carrier, as these have previously been reported, with SNCA multiplications having
particular low penetrance levels in Asian populations (Ahn et al., 2008; Nishioka et al., 2006a). It is
also possible the duplication reported is an artifact caused by the creation or passage of the
lymphoblast cell lines used to extract DNA (Simon-Sanchez et al., 2007).
We also identified one heterozygous duplication encompassing CHCHD10, a gene previously
shown to cause FTD. However, given that CHCHD10 FTD-associated mutations are loss-of-function
(Perrone et al., 2017), it is unlikely that a duplication of the gene would be pathogenic.
GABRB3 is a gamma-aminobutyric acid (GABA) receptor that was reported as associated with DLB
in a recent GWAS, but that did not survive independent replication (Guerreiro et al., 2018).
However, loss of GABA receptors could underlie the typical visual hallucinations in DLB (Khundakar
et al., 2016), and, because of this, we specifically looked at CNVs in GABRB3, and identified a
duplication in one case. It is tempting to speculate that, given the GWAS discovery results, the fact
that GABA receptors neurotransmission is altered in DLB (Santpere et al., 2017), and the CNV
detected here, genetic variability in GABA receptors may in fact modulate risk for DLB.
We identified two clinically diagnosed DLB samples with MAPT duplications (Figure 3). MAPT was
not found to be significantly associated with DLB in recent GWAS (Bras et al., 2014; Guerreiro et al.,
2018), but the MAPT H1 haplotype was previously described as a possible risk factor for DLB
(Cervera-Carles et al., 2016; Labbé et al., 2016). Previous studies of small cohorts of FTD patients
have not revealed causative MAPT duplications (Lladó et al., 2007; Skoglund et al., 2009) but the
screening of French FTD patients including multiplex families led to the identification of an
heterozygous partial deletion of MAPT (Rovelet-Lecrux et al., 2009) and of a 17q21.31
microduplication in an atypical FTD case (Rovelet-Lecrux et al., 2010). More recently, MAPT
duplications were shown to increase expression of MAPT mRNA and were found to cause tangle
pathology without Aβ deposition in probable AD patients (Le Guennec et al., 2017).  
PARK2 homozygous CNVs are the most common copy-number cause of PD, accounting for more
than 50% of all pathogenic mutations in the gene and more frequently affecting the region between
exons 2 and 7 (Hedrich et al., 2004; Kim et al., 2012). Our results showed no significant differences
between DLB cases and controls, similar to the findings by Kay and colleagues in PD (Kay et al.,
2010). Additionally, we did not find any homozygous PARK2 CNVs suggesting that CNVs in this
gene do not play a causative role in DLB.
APP duplications are known to cause AD (Delabar et al., 1987; Ghani et al., 2012; Swaminathan et
al., 2012, 2011; Zheng et al., 2015, 2014). The sample carrying an APP duplication in our cohort
has a clinical diagnosis of DLB without neuropathological confirmation - it is therefore possible this
is an AD case misdiagnosed as DLB. However, there have been reports in the literature of DLB
cases associated with APP duplications. For example, in a French family presenting with a diverse
phenotype, APP duplication was associated with DLB confirmed by neuropathological findings
(Guyant-Marechal et al., 2008). Similarly, one case with Lewy body-variant AD was reported in a
multigenerational dementia family from the Netherlands (Sleegers et al., 2006). DLB cases
frequently present Aβ pathology at autopsy (Hepp et al., 2016), and it has been suggested that Aβ 
accumulation can trigger Lewy body disease (Masliah et al., 2001).
There are two main limitations in this study: first, this is a relatively small-sized cohort, which means
we cannot confidently assess associations of CNVs with low effect sizes on disease; second, we did
not perform independent replication of these findings, which precludes us from establishing definite
associations or causes of disease. Despite these limitations we report on the first systematic
analysis of CNVs in a large cohort of DLB patients, using well-established analytical practices. We
identify potential disease causing CNVs as well as potential novel candidate genes for DLB.
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Figures captions
Figure 1. Schematic representation of CNVs.
Schematic representation of statistically significant CNVs resulting from the case-control analysis that
were not found in controls or publicly available databases. CNVs overlapping LAPTM4B in A; and
SPAG9/NME1 in B. Known transcripts are represented at the bottom of each panel. Passing QC
SNPs used for the CNV calling are depicted by colour according to the genotyping array (red:
OmniExpress, blue: Omni2.5M, green: Omni2.5M for controls). CNVs (duplications) are depicted as
bars above the genes. The grey shadow area represents the associated region that is genome-wide
significant.
Figure 2. Duplication identified at the SNCA locus.
Log R ratio and B allele frequency plots of the CNV identified in the SNCA locus. Each point
represents a SNP according to location in chromosome 4 (position on X axis). The genomic
duplication is indicated by an increase in log R ratio and B allele frequency clusters outside the
expected values of 1 (B/B), 0.5 (A/B), and 0 (A/A). Genes are represented at the bottom as black
bars. SNPs inside the CNV region are represented in red, SNPs outside the CNV region are
represented in blue, and SNPs in SNCA are represented in green.
Figure 3. Duplications identified at the MAPT locus.
Log R ratio and B allele frequency plots of the CNVs identified at the MAPT locus in two clinically
diagnosed DLB cases. Each point represents a SNP according to location in chromosome 17 (position
on X axis). The genomic duplication is indicated by an increase in log R ratio and B allele frequency
clusters outside the expected values of 1 (B/B), 0.5 (A/B), and 0 (A/A). Genes are represented at the
bottom as black bars. SNPs inside the CNV regions are represented in red, SNPs outside the CNV
regions are represented in blue, and SNPs in MAPT are represented in green.
Tables
Table 1 Results from the three types of analyses performed
Genes Location CNV p-value Cases(Neuro*) Controls
Cases
frequency
Controls
frequency
DGV
frequency
DECIPHER
frequency
Case-control association analysis
ADGRG7,TFG chr3:100357671-100439759 Gain 8.93x10-5 21 (18) 13 1.77x10-2 9.10x10-3 1.43x10-2 2.09x10-2
PDZD2 chr5:32101400-32106628 Gain 2.94x10-6 14 (12) 0 1.18x10-2 0 3.00x10-4 1.69x10-4
LAPTM4B chr8:98755434-98800334 Loss 6.29x10-7 12 (6) 0 1.01x10-2 0 0 0
MSR1 chr8:15948235-16021468 Loss 1.20x10-4 13 (7) 4 1.10x10-2 2.80x10-3 4.30x10-3 7.10x10-3
NME1,NME1-NME2,SPAG9 chr17:49177096-49231786 Loss 2.72x10-4 9 (4) 0 7.58x10-3 0 0 0
Candidate CNVs approach
CSMD1 chr8:4,033,908-4,126,540 Loss 2.89x10-2# 3 (2) 0 2.53x10-3 0 3.00x10-4 0
DDX11,OVOS2 chr12:31,249,834-31,407,303 Gain 1.41x10-2# 4 (2) 0 3.37x10-3 0 4.61x10-2 0
CYFIP1,GOLGA8I,NIPA1,NIPA2,TUBGCP5,
WHAMML1 chr15:22,750,305-23,272,733 Gain na 5 (5) 8 4.21x10
-3 5.60x10-3 2.50x10-3 1.86x10-3
CHRNA7,OTUD7A chr15:31,932,865-32,515,849 Loss or Gain na 6 (5) 13 5.05x10-3 9.10x10-3 6.90x10-3 8.79x10-3
ASPHD1,BOLA2,C16orf54,CDIPT,CDIPT-AS1,
KIF22,MAZ,MVP,PAGR1,PRRT2,QPRT,SEZ6L2,
SPN,ZG16
chr16:29,595,483-29,912,902 Gain na 1 (1) 0 8.42x10-4 0 0 1.69x10-4
Candidate genes approach
DNAJC6,LEPR,LEPROT chr1:65,854,556-65,955,725 Gain na 1 (0) 1 8.42x10-4 7.00x10-4 1.72x10-4 2.53x10-3
SNCA,SNCA-AS1,GPRIN3,MMRN1,CCSER1 chr4:90,035,549-91,420,358 Gain na 1 (1) 0 8.42x10-4 0 6.42x10-4 0
PARK2 chr6:161,601,162-163,259,260 Loss or Gain na 13 (8) 28 1.10x10-2 1.96x10-2 2.30x10-3 1.69x10-1
GABRB3,GABRA5 ,GABRG3 chr15:26,996,126-27,220,713 Gain na 1 (1) 0 8.42x10-4 0 0 1.18x10-3
MAPT,CRHR1,KANSL1,KANSL1-AS1,
MAPT-AS1,MAPT-IT1,SPPL2C,STH chr17:43,661,362-44,345,063 Gain na 2 (0) 0 1.68x10
-3 0 1.03x10-4 1.18x10-3
APP,ADAMTS1,ADAMTS5,ATP5J,CYYR1,
CYYR1-AS1,GABPA,JAM2,MRPL39 chr21:25,063,840-28,522,487 Gain na 1 (0) 0 8.42x10
-4 0 0 0
CHCHD10,ADORA2A,ADORA2A-AS1,C22orf15,
CABIN1,CES5AP1,DDT,DDTL,DERL3,DRICH1,G
GT1,GGT5,GSTT1,GSTT1-AS1,GSTT2,GSTT2B,
GSTTP1,GSTTP2,GUCD1,GUSBP11,IGLL1,
LRRC75B,MIF,MIF-AS1,MMP11,POM121L9P,
RGL4,SLC2A11,SMARCB1,SNRPD3,SPECC1L,
SUSD2,UPB1,VPREB3, ZDHHC8P1,ZNF70
chr22:23,690,325-25,011,417 Gain na 1 (1) 0 8.42x10-4 0 6.00x10-4 1.18x10-3
CYP2D6,NDUFA6-AS1 chr22:42,522,613-42,531,210 Loss or Gain na 1 (1) 4 8.42x10-4 2.80x10-3 2.20x10-1 3.00x10-2
CNVs identified as significantly associated with DLB in the case-control association analyses and
CNVs identified using the candidate CNVs and genes approaches.
All genomic coordinates are for the genome assembly hg19. * Neuropathological diagnosis; na – not
applicable; p-value - these were calculated including all cases (not only neuropathologically confirmed
cases) # – p-values resulting from the case-control association analysis.
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